📣 Our lead scientist Maxime FREDON and its co-authors published the fantastic work of design, evaluation and selection of the ScFv of CARLA001 our CD123 CAR-T Cell programme. This makes our CAR-T Cell unique because designed to have the right balance between efficacy and safety an essential key feature for clinical success. Congratulations to the whole team ! UMR Right Université de Franche-Comté Francine Garnache Ottou Olivier Adotevi Fanny Delettre Elodie BÔLE-RICHARD Région Bourgogne-Franche-Comté Landmark BioVentures AG EFS DECA-BFC Mehdi Chelbi Zaki Sellam
I'm delighted to share with you some of the work I carried out during my thesis at the UMR Right, EFS in Besançon. We have shown that it is essential to evaluate different scFvs in order to select one that strikes the right balance between efficacy and safety. Thank you to all the co-authors for their contributions, Margaux Poussard sabeha biichle Francis Bonnefoy Charles-Frédéric Mantion Evan Seffar Florian Renosi Elodie BÔLE-RICHARD Romain Boidot Sandrine Chevrier François Anna Maria Loustau Julien Caumartin Mathieu G. Eric Robinet - Fondateur Lymphobank Philippe Saas Eric DECONINCK ETIENNE DAGUINDAU Xavier Roussel YANN GODET Olivier Adotevi Fanny Delettre Jeanne Galaine Francine Garnache Ottou, our external collaborators and to our financial partners, université de Franche-Comté CHU de Besançon Medix Biochemica LYMPHOBANK Association Laurette Fugain Région Bourgogne-Franche-Comté Institut national du cancer